The biotechnology company Amgen was founded in 1980 as AMGen. With approximately 20,000 employees, Amgen is one of the world's largest biotechnology companies with annual sales of approximately $ 24 billion in 2018.
According to Amgen's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 19.441. At the end of 2022 the company had a P/E ratio of 21.6.
Year | P/E ratio | Change |
---|---|---|
2022 | 21.6 | -0.7% |
2021 | 21.7 | 17.02% |
2020 | 18.6 | -0.31% |
2019 | 18.6 | 21.35% |
2018 | 15.3 | -76.8% |
2017 | 66.1 | 366.71% |
2016 | 14.2 | -20.05% |
2015 | 17.7 | -24.46% |
2014 | 23.5 | 38.6% |
2013 | 16.9 | 9.96% |
2012 | 15.4 | -2.67% |
2011 | 15.8 | 38.85% |
2010 | 11.4 | -8.79% |
2009 | 12.5 | -18.26% |
2008 | 15.3 | -7.89% |
2007 | 16.6 | -39.3% |
2006 | 27.3 | 2.56% |
2005 | 26.6 | -22.75% |
2004 | 34.5 | -2.88% |
2003 | 35.5 | -167.58% |
2002 | -52.5 | -198.68% |
2001 | 53.2 |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.